首页> 美国卫生研究院文献>BioMed Research International >Potential Diagnostic and Prognostic Biomarkers of Circular RNAs for Lung Cancer in China
【2h】

Potential Diagnostic and Prognostic Biomarkers of Circular RNAs for Lung Cancer in China

机译:中国肺癌环状RNA的潜在诊断和预后标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Emerging evidence demonstrated that circular RNAs (circRNAs) were dysregulated in lung cancer, indicating that circRNAs might serve as novel diagnostic and prognostic biomarkers for lung cancer. However, the clinical value of circRNAs on lung cancer remains unclear. This study aimed to evaluate the efficiency of circRNAs in the diagnosis and prognosis for lung cancer in China. 2122 Chinese individuals were enrolled in this investigation for assessment of diagnostic value and examination of prognostic analysis. In the diagnostic analysis, the pooled sensitivity, specificity, PLR, NLR, DOR, and AUC of the sROC curve with their 95% CIs were 0.80 (95%CI: 0.74-0.84), 0.80 (95%CI: 0.73-0.86), 3.97 (95%CI: 2.80-5.62) and 0.26 (95%CI: 0.19-0.34), 15.51 (95%CI: 8.76-24.47), and 0.85 (95%CI: 0.82-0.88), respectively. As for the prognostic power of circRNAs, lung cancer patients with higher expression levels of circRNAs tend to possess lower overall survival with the overall pooled HR (1.70, 95%CI: 1.26-2.29). Furthermore, in stratified analysis, upregulated and downregulated circRNAs were manifested to exert significant effects on prognosis with HR values of 2.17 (95%CI: 1.74-2.72) and 0.52 (95%CI: 0.34-0.80). This study validates that circRNAs are promising diagnostic and predictive biomarkers for lung cancer patients in China.
机译:越来越多的证据表明,环状RNA(circRNA)在肺癌中失调,表明circRNA可能作为肺癌的新型诊断和预后生物标志物。但是,circRNA在肺癌上的临床价值尚不清楚。本研究旨在评估circRNAs在中国肺癌诊断和预后中的有效性。本研究共纳入2122名中国人,以评估其诊断价值和检查预后。在诊断分析中,sROC曲线及其95%CI的合并敏感性,特异性,PLR,NLR,DOR和AUC分别为0.80(95%CI:0.74-0.84),0.80(95%CI:0.73-0.86)分别为3.97(95%CI:2.80-5.62)和0.26(95%CI:0.19-0.34),15.51(95%CI:8.76-24.47)和0.85(95%CI:0.82-0.88)。至于circRNA的预后能力,具有较高circRNA表达水平的肺癌患者往往具有较低的总生存率(合并总HR)(1.70,95%CI:1.26-2.29)。此外,在分层分析中,circRNA的上调和下调被证明对预后有显着影响,HR值分别为2.17(95%CI:1.74-2.72)和0.52(95%CI:0.34-0.80)。这项研究验证了circRNA在中国肺癌患者中有望成为诊断和预测生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号